Bank Julius Baer & Co. Ltd Zurich Sells 13,580 Shares of Zoetis Inc. $ZTS

Bank Julius Baer & Co. Ltd Zurich lowered its position in Zoetis Inc. (NYSE:ZTS) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 659,198 shares of the company’s stock after selling 13,580 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Zoetis were worth $82,955,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth approximately $25,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Zoetis in the third quarter valued at approximately $31,000. Lodestone Wealth Management LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $30,000. Holos Integrated Wealth LLC bought a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund bought a new position in shares of Zoetis during the 4th quarter worth approximately $38,000. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In related news, Director Frank A. Damelio purchased 6,650 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael B. Mccallister purchased 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders purchased 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Trading Down 3.4%

ZTS stock opened at $74.32 on Thursday. Zoetis Inc. has a 52 week low of $74.29 and a 52 week high of $172.23. The company has a market capitalization of $31.16 billion, a PE ratio of 12.33, a price-to-earnings-growth ratio of 1.26 and a beta of 0.87. The company’s 50-day simple moving average is $114.33 and its 200 day simple moving average is $121.77. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the firm earned $1.48 EPS. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.89 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ZTS shares. UBS Group dropped their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Bank of America increased their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Seven research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $141.25.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.